INTRODUCTION
============

Exogenously applied arachidonic acid (AA) or stimulation of certain G~q~-coupled receptors (G~q~PCRs) enhances as well as inhibits N current ([@bib1]; [@bib27]; [@bib25]; and see Heneghan et al. in this issue). In [@bib15], we found that the form of modulation observed depends on which accessory Ca~V~β subunit is coexpressed with Ca~V~2.2. When Ca~V~β1b, Ca~V~β3, or Ca~V~β4 is present, AA (or receptor agonist) rapidly enhances N current; however, enhancement quickly progresses to robust inhibition. In contrast, currents from Ca~V~β2a-containing channels exhibit sustained enhancement. Of the known Ca~V~β subunits, only Ca~V~β2a is palmitoylated on its two N-terminal cysteine residues ([@bib8]; [@bib43]). We hypothesized that persistent enhancement may result from the palmitoyl groups of Ca~V~β2a assuming a position within the membrane that prevents AA from interacting with the N channel\'s inhibitory sites. In support of this possibility, we found that AA no longer enhanced but instead inhibited N current from channels containing a depalmitoylated Ca~V~β2a (Ca~V~β2a(C3,4S); [@bib8]). Additionally, when Ca~V~β2a\'s N terminus was substituted into Ca~V~β1b to form the chimera Ca~V~β2a/β1b ([@bib9]), N current was no longer inhibited, but instead enhancement was observed, which is consistent with the palmitoyl groups preventing inhibition. Lastly, exogenously applied palmitic acid successfully minimized the inhibition normally observed with Ca~V~β3. Collectively, these findings suggest that the palmitoyl groups are sufficient for preventing N-current inhibition by the slow pathway. This signal transduction cascade is initiated by G~q~PCRs that use PIP~2~ breakdown ([@bib51]; [@bib12]), resulting in release of a free fatty acid, most likely AA ([@bib25]; [@bib28]; [@bib15]).

From these findings, we proposed the following model to explain loss of inhibition in the presence of Ca~V~β2a: AA is released after G~q~PCR stimulation of phospholipid breakdown ([Fig. 1 A](#fig1){ref-type="fig"}). Once released, AA normally binds to an inhibitory site on the channel. However, when Ca~V~β2a is present, its palmitoyl groups occupy the inhibitory site blocking AA\'s interaction with Ca~V~2.2 ([Fig. 1 B](#fig1){ref-type="fig"}). For the palmitoyl groups of Ca~V~β2a to interact with a specific site on Ca~V~2.2, we predicted that Ca~V~β2a must reside in a specific orientation so that the palmitoyl groups situate close to or overlapping with the channel\'s inhibitory site. To determine whether such an interaction might occur, in this study we tested whether changing Ca~V~β2a\'s orientation relative to Ca~V~2.2 rescues inhibition.

![Ca~V~2.2 model system to be tested by NK-1R activation. (A) Flow chart representing the signaling cascade used by SP to modulate N current. (B) Schematic of model to be tested: N channels consist of the pore-forming Ca~V~2.2, which is made up of four homologous domains (I--IV) also referred to as pseudosubunits, α~2~δ-1, and a Ca~V~β. Palmitoylated Ca~V~β2a blocks endogenously liberated free AA from binding to Ca~V~2.2\'s inhibitory sites after exposure of cells to SP. AA\'s enhancement site remains available and is shown here in the outer regions of Ca~V~2.2, although the actual location of this site remains uncharacterized. (C) Topological organization of Ca~V~2.2 showing the six transmembrane segments and pore loop (P) of each pseudosubunit. An intracellular linker tethers each pseudosubunit to the subsequent one. Ca~V~β binds the AID region on the I--II linker at a site (delineated by the dotted box) that overlaps with a binding site for Gβγ. (D) The amino acid deletions in the region proximal to the AID result in Bdel1 and Bdel2 mutant channels. (E) Cross-sectional views from the inner pore region of wt Ca~V~2.2 and the two mutant channels. Sequential amino acid deletions in the IS6-AID segment of Bdel1 and Bdel2 are predicted to reorient Ca~V~β2a such that the two palmitoyl groups (small white circles) are displaced from their wt positions.](JGP_200910204R_RGB_Fig1){#fig1}

All Ca~V~βs bind with high affinity to the cytoplasmic linker between domains I and II ([Fig. 1 C](#fig1){ref-type="fig"}) at the α interacting domain (AID; [@bib34]; [@bib7]; [@bib33]; [@bib44]). The region proximal to the AID appears to couple Ca~V~β\'s movements to tune the gating properties of the channel, possibly by modulating the movements of IS6 ([@bib46]; [@bib53]). This IS6-AID segment appears to form, in part, a rigid helical structure that regulates the orientation of Ca~V~β2a and consequently its secondary interactions with Ca~V~2.2. Deleting one (Bdel1) or two (Bdel2) amino acids in the IS6-AID segment ([Fig. 1 D](#fig1){ref-type="fig"}) changes the orientation of Ca~V~β2a to Ca~V~2.2 ([Fig. 1 E](#fig1){ref-type="fig"}) with each shift in the helix ([@bib46]). Therefore, we tested Bdel1 and Bdel2 mutants coexpressed with Ca~V~β2a for sensitivity to substance P (SP). Bdel1 exhibited minimal current enhancement, whereas Bdel2 rescued current inhibition by the slow pathway. In turn, exogenous palmitic acid reduced this inhibition. These findings are consistent with a model in which the orientation of a palmitoylated cytoplasmic protein, Ca~V~β2a, alters the regulation of the transmembrane protein, Ca~V~2.2. This model raises the possibility that other cytosolic proteins may use their palmitoyl groups to interact with transmembrane segments of associated proteins to modify their behavior.

MATERIALS AND METHODS
=====================

Site-directed mutagenesis
-------------------------

The cDNA encoding the rat brain Ca~V~2.2 (GenBank/EMBL/DDBJ accession no. [AF055477](AF055477)) was subcloned into the plasmid vector pcDNA6 ([@bib24]) and was provided by D. Lipscombe (Brown University, Providence, RI). To make the mutant Bdel1 and Bdel2 cDNAs, a 1.5-kb fragment was subcloned into pCR2.1-TOPO (Invitrogen) and mutated using the QuikChange protocol and Pfu Ultra DNA polymerase (Agilent Technologies). Oligonucleotide primers, which were obtained from Invitrogen, were used without purification. All restriction enzymes were purchased from New England Biolabs, Inc. The full-length cDNA was reassembled in the original plasmid vector that was cut with AscI and BsiWI by ligating the following fragments: AscI(32)--BlpI(355), BlpI--SacI(1407), and SacI--BsiWI(2991). The Bdel1 and Bdel2 amino acid deletions were contained in the BlpI--SacI fragment. The sequence of this fragment was verified for each mutant by automated sequencing at the University of Virginia Biomolecular Research Facility.

Transfection
------------

Human embryonic kidney (HEK) cells with a stably transfected M~1~ receptor (M~1~R; HEK-M1) were grown at 37°C with 5% CO~2~ in Dulbecco\'s modified Eagle\'s medium/F12 supplemented with 10% FBS, 1% G418, 0.1% gentamicin, and 1% HT supplement (Invitrogen). For transfection, cells were plated in 12-well plates at 50--80% confluency. Cells were transiently transfected using Lipofectamine PLUS reagent (Invitrogen) as per the manufacturer\'s instructions. The transfection mixture consisted of plasmids encoding wild-type (wt) or mutant Ca~v~2.2 e\[^a^10, Δ18a, Δ24a, 31a, 37b, 46\] (GenBank accession no. [AF055477](AF055477); [Fig. 1, C and D](#fig1){ref-type="fig"}; [@bib46]), α~2~δ-1 (GenBank accession no. [AF286488](AF286488)), and either Ca~V~β2a (GenBank accession no. [M80545](M80545)) or Ca~V~β3 (GenBank accession no. [M88751](M88751)) at a 1:1:1 molar ratio. 28 ng/well of plasmid encoding neurokinin-1 receptor (NK-1R; GenBank accession no. [AY462098](AY462098); UMR cDNA Resource Center, University of Missouri, Rolla, MO) and enhanced green fluorescent protein cDNA (used at \<10% of total cDNA) were also included in the transfection medium. Cells were plated on poly-[l]{.smallcaps}-lysine--coated coverslips 24--72 h after transfection. However, currents elicited from Bdel1 and Bdel2 mutants were not detectable. To boost mutant channel expression by increasing transcription, 80 ng of plasmid containing the SV40 T antigen was included during transfection. Currents were recorded between 24 and 76 h after transfection.

Electrophysiology
-----------------

Whole-cell Ba^2+^ currents were recorded at room temperature (20--24°C) using a patch-clamp amplifier (model 3900a; Dagan Instruments Inc.). Currents were filtered at 1--5 kHz using the amplifier\'s four-pole low-pass Bessel filter and digitized at 20 kHz with a micro1401 interface (Cambridge Electronic Design \[CED\]). Data were acquired and analyzed using either IPLab 4.0 (Scanalytics) as described previously ([@bib45]) or Signal 2.16 (CED) and stored on a personal computer. Before analysis, capacitive and leak currents were subtracted using a scaled-up hyperpolarizing test pulse to −100 mV. For all recordings, cells were held at −90 mV and given either a 24- or 100-ms depolarization to the test pulse indicated. Unless mentioned, the protocol was repeated every 4 s. For prepulse experiments, a 24-ms depolarization (P1) was followed 250 ms later by a step depolarization to 120 mV for 25 ms, then followed 30 ms later by another 24-ms depolarization (P2) and repeated every 10 s ([Fig. 2 C](#fig2){ref-type="fig"}). Electrodes were pulled from borosilicate glass capillary tubes. Each electrode was fire polished to ∼1 µm to yield pipettes with resistances of 2--3 MΩ. The external solution contained 125 mM NMG-aspartate, 10 mM HEPES, and 5 or 20 mM barium (Ba^2+^) acetate; pH was adjusted to 7.5 with CsOH. When the Ba^2+^ concentration was lowered from 20 to 5 mM (for recording wt Ca~v~2.2 currents), 135 mM NMG-aspartate was substituted for Ba^2+^. The internal solution of the pipette consisted of 135 mM Cs-aspartate, 10 mM HEPES, 0.1 mM 1,2-bis(*O*-aminophenoxy) ethane-*N*,*N*,*N*',*N*'-tetraacetic acid (BAPTA), 5 mM MgCl~2~, 4 mM ATP, and 0.4 mM GTP; the pH was adjusted to 7.5 with CsOH. When 20 mM BAPTA was included in the pipette solution, the Cs-aspartate concentration was lowered accordingly in the internal solution.

![NK-1R activation enhances Ca~v~2.2/Ca~V~β2a currents. HEK-M1 cells were transiently transfected with Ca~V~2.2, α~2~δ-1, β2a, and NK-1R. (A) Individual traces taken before and 2 min after application of 5 nM SP. (left) 0.1 mM BAPTA was present in the internal solution. (right) 20 mM BAPTA in the internal solution. (B) Comparison of the mean percent enhancement for cells dialyzed with 0.1 or 20 mM BAPTA (*n* = 4--9); \*, P \< 0.05 compared with inhibition in the presence of 0.1 mM BAPTA. (C) Individual traces taken before and 2 min after application of SP. P1 and P2 represent current measured before and after a prepulse, respectively. (D) Summary of the percent enhancement by SP at 0 mV before and after a prepulse (*n* = 9); \*, P \< 0.05 compared with P1 and P2 control currents before SP application. (E) Averaged current--voltage relationships measured before (closed circles) and after (open circles) application of SP. (F) Summary of TTP before and after application of SP (*n* = 6); \*, P \< 0.05 compared with control. Error bars represent SEM. Bars, 10 ms and 200 pA.](JGP_200910204_RGB_Fig2){#fig2}

Bimolecular fluorescence complementation (BiFC)
-----------------------------------------------

BiFC imaging was performed as previously described ([@bib46]). In brief, a small C-terminal (amino acids 159--238) sequence of cyan fluorescent protein (CFP) was fused to the C terminus of full-length Ca~V~β2a ([Fig. S1 A](http://www.jgp.org/cgi/content/full/jgp.200910204/DC1)). The big N-terminal fragment of CFP (amino acids 1--158) was fused to the N terminus of Ca~V~2.2, Bdel1, or Bdel2. Plasmids encoding 250 ng Ca~V~2.2, Bdel1, or Bdel2, 1 µg α~2~δ-1, and 1 µg of full-length β2a were transiently transfected into HEK-293 cells. After 18 h, the cells were plated onto poly-[l]{.smallcaps}-lysine--treated glass-bottom dishes (Fluorodish; World Precision Instruments). BiFC was visualized by cyan fluorescence signals that were collected with IPLab software and a Sensicam QE (Cooke) mounted on a microscope (100× objective and 2 × 2 binning; IX61; Olympus) equipped with a confocal spinning disk unit (Olympus). Digital images were background subtracted using a region devoid of cells.

Pharmacology
------------

SP was prepared as a 0.5-mM stock solution in 0.05 M acetic acid and stored at −20°C. To make a working concentration of 5 nM, the stock was serially diluted with bath solution daily. Palmitic acid was dissolved in 100% ethanol to make a stock solution. Working solutions were made by diluting the stock 1:1,000 with bath solution. BSA (fraction V, heat shock, fatty acid ultra free; Roche) was dissolved in the bath solution and diluted further to make a final concentration of 1 mg/ml. All chemicals were obtained from Sigma-Aldrich except where noted. Drugs were applied with a gravity-driven perfusion system, and complete bath exchange was achieved within 10--14 s.

Data analysis
-------------

After the onset of the test pulse, maximal inward current of whole-cell traces was measured using a trough-seeking function. Percent change in current amplitude was measured as \[(I − I')/I\] × 100, where I is the mean amplitude of peak current measured from five current traces before drug application and I' is the mean current amplitude measured from five current traces at least 2 min after application of SP, unless otherwise noted.

Statistical analysis
--------------------

Summary data are presented as mean ± SEM. Mean current amplitude before and after application of SP was compared using a two-tailed paired *t* test. Two means were compared using a two-way Student\'s *t* test. Statistical significance was set at P \< 0.05. Data were analyzed using Excel (Microsoft) and Origin (OriginLab).

Online supplemental material
----------------------------

Fig. S1 shows BiFC images of Ca~V~2.2, Bdel1, and Bdel2 colocalizing with Ca~V~β2a to the plasma membrane. Online supplemental material is available at <http://www.jgp.org/cgi/content/full/jgp.200910204/DC1>.

RESULTS
=======

SP enhances wt Ca~v~2.2 current via a BAPTA-sensitive, voltage-independent pathway
----------------------------------------------------------------------------------

We characterized several biophysical properties of N-current enhancement by SP. In HEK-M1 cells transfected with Ca~V~2.2, Ca~V~β2a, α~2~δ-1, and the NK-1R, we first tested whether as with inhibition, the enhancement of N current occurs via a BAPTA-sensitive pathway. In cells dialyzed with a low (0.1 mM) BAPTA concentration, application of 5 nM SP enhanced N current 62 ± 18% ([Fig. 2, A \[left\] and B](#fig2){ref-type="fig"}). In contrast, when cells were dialyzed with a high (20 mM) BAPTA concentration for at least 2 min to chelate intracellular Ca^2+^, SP no longer elicited current modulation ([Fig. 2, A \[right\] and B](#fig2){ref-type="fig"}). Thus, enhancement involves a BAPTA-sensitive pathway similar to that shown earlier for M~1~R-mediated N-current inhibition ([@bib2]; [@bib3]; [@bib30]; [@bib27]; [@bib25]).

Second, we tested whether enhancement, as with inhibition, is insensitive to prepulse facilitation of current. Similar to our previous studies using exogenously applied AA ([@bib1]; [@bib27]), M~1~R agonist ([@bib25]), or SP activation of NK-1Rs ([@bib15]), current enhancement occurred between −10 and 0 mV ([Fig. 2, C--E](#fig2){ref-type="fig"}). Current--voltage (I-V) plots revealed that maximal enhancement occurred 10 mV negative to the voltage that elicited peak inward current---in this case at 0 mV ([Fig. 2 E](#fig2){ref-type="fig"}). Thus, we measured N current over time by stepping to a test potential 10 mV to the left of where maximal inward current occurs. Using this protocol, a slight relief from tonic inhibition was observed under control conditions; however, after SP application, both P1 and P2 currents exhibited similar significant (P \< 0.05) enhancement (62 ± 18% and 50 ± 11%, respectively) compared with control currents ([Fig. 2, C and D](#fig2){ref-type="fig"}).

AA-induced enhancement of N current coincides with an increased rate of activation in SCG neurons ([@bib1]). Therefore, in a third study, we examined whether enhancement by SP involves an increase in activation kinetics, detected as a change in time to peak (TTP) inward current. We measured the TTP of N current before and after application of SP. As shown in [Fig. 2 F](#fig2){ref-type="fig"}, SP significantly decreased TTP (P \< 0.05; *n* = 6) when Ca~V~β2a was coexpressed with Ca~V~2.2 similar to native N current ([@bib1]). Collectively, these tests indicate that in addition to recapitulating the properties of native N-current enhancement, recombinant N-current enhancement exhibits similar properties to N-current inhibition by SP: sensitivity to the internal BAPTA concentration but unaltered by prepulses.

Modulation of Bdel1 current by SP is disrupted
----------------------------------------------

We next examined whether mutant Ca~V~2.2 channels coexpressed with Ca~V~β2a exhibit similar modulation by SP. Bdel1 has a single amino acid deletion in the IS6-AID segment ([@bib46]) that reorients Ca~V~β2a\'s position relative to Bdel1 ([Fig. 1, D and E](#fig1){ref-type="fig"}). We hypothesized that this deletion may sufficiently move Ca~V~β2a such that the palmitoyl groups no longer occupy the putative inhibitory site so that SP will now inhibit rather than enhance current. Although SP enhanced Bdel1 currents in seven of seven cells ([Fig. 3 A](#fig3){ref-type="fig"}), enhancement varied from as little as 12% to as high as 135% and thus was not significant ([Fig. 3, B and C](#fig3){ref-type="fig"}). To rule out the possibility that inhibition was disrupted as a result of a change in the inhibitory site, we tested Bdel1 coexpressed with Ca~V~β3 for modulation by SP. Indeed, SP inhibited currents of Bdel1/Ca~V~β3 channels by 32 ± 10% (P \< 0.05; [Fig. 3, D and E](#fig3){ref-type="fig"}). The magnitude of inhibition did not differ significantly from wt Ca~V~2.2/β3 currents, indicating that the site of inhibition remained unaffected by the amino acid deletion in the IS6-AID segment. Moreover, no facilitation of modulated currents was observed with Bdel1 whether expressed with Ca~V~β2a ([Fig. 3, B and C](#fig3){ref-type="fig"}) or Ca~V~β3 ([Fig. 3, D and E](#fig3){ref-type="fig"}).

![Modulation of Bdel1 current by SP is modestly disrupted. HEK-M1 cells were transiently transfected with NK-1R, Bdel1, α~2~δ-1, β2a (A--C), or β3 (D and E). (A) Averaged current--voltage plots measured before and after application of SP (red). (B and C) Individual sweeps elicited at 20 mV (B) and summary of enhancement (C) taken before and 2 min after application of SP (red) before (P1) or after a prepulse (P2; *n* = 7). (D) Representative sweeps taken before and 2 min after application of SP. (E) Summary of the inhibition by SP at 20 mV caused by SP before (P1) and after a prepulse (P2; *n* = 4); \*, P \< 0.05 compared with control currents. Error bars represent SEM. Bars, 10 ms and 200 pA.](JGP_200910204R_RGB_Fig3){#fig3}

SP inhibits Bdel2 currents in the presence of palmitoylated β2a
---------------------------------------------------------------

To determine whether an additional amino acid deletion further alters N-current modulation, we tested the effects of SP on Bdel2 activity. We hypothesized that deletion of two amino acids ([Fig. 1 D](#fig1){ref-type="fig"}) might further displace Ca~V~β2a from its normal position ([Fig. 1 E](#fig1){ref-type="fig"}), resulting in a more obvious disruption of N-current enhancement. After application of SP, robust inhibition of Bdel2 current was observed rather than enhancement ([Fig. 4, A, B, and E](#fig4){ref-type="fig"}). Inhibition was observed at all voltages ([Fig. 4 A](#fig4){ref-type="fig"}) and was not relieved by a prepulse (P1, 46 ± 7% vs. P2, 45 ± 8% at 10 mV). When inhibition of Bdel2/β2a currents was compared with inhibition of Ca~V~2.2/β3 currents ([Fig. 4, B and C](#fig4){ref-type="fig"}), the magnitude of inhibition was similar and was not relieved by a prepulse ([Fig. 4, D and E](#fig4){ref-type="fig"}). Overall, current modulation by SP exhibited unique properties with each change in the orientation of Ca~V~β2a: enhancement of N current, normally observed with Ca~V~2.2/β2a channels, became more variable with Bdel1/β2a channels, whereas Bdel2/β2a currents exhibited robust inhibition similar to Ca~V~2.2/β3 current modulation ([Fig. 4 E](#fig4){ref-type="fig"}).

![NK-1R activation inhibits Bdel2 currents. HEK-M1 cells were transiently transfected with Bdel2, α~2~δ-1, Ca~V~β2a, or Ca~V~β3 and NK-1R. (A) Averaged current--voltage plot measured before and after application of SP. (B and C) Individual traces from Ca~V~β2a-containing Bdel2 channels (B) or Ca~V~β3-containing wt channels (C) taken before and 2 min after application of SP (red) before (P1) or after a prepulse (P2). (D) Prepulse facilitation (ratio of P2/P1) for wt Ca~V~2.2 (▪), Bdel1 (•), and Bdel2 with either Ca~V~β2a (▴) or Ca~V~β3 (▾); \*, P \< 0.05 compared with Bdel1. (E) Summary of modulation of wt Ca~V~2.2 (▪), Bdel1 (•), and Bdel2 with either Ca~V~β2a (▴) or Ca~V~β3 (▾) by SP before (closed) and after (open) a prepulse; \*, P \< 0.05 compared with control currents (*n* = 4--9). Error bars represent SEM. Bars, 10 ms and 200 pA.](JGP_200910204R_RGB_Fig4){#fig4}

It is unlikely that differences in modulation are caused by the loss of Ca~V~β binding to Bdel1 because normally little to no current is observed when Ca~V~β is left out of the transfection ([@bib46]). We also found that when Bdel2 was cotransfected with only α~2~δ-1, mean current amplitude was −11 ± 7 pA (*n* = 3), indicating that to observe currents Ca~V~β must be bound to channels. Additionally, to confirm that differences in modulation of Bdel mutants compared with wt Ca~v~2.2 are not caused by the loss of Ca~V~β expression, we performed BiFC analysis ([@bib21]; [@bib46]) using Ca~V~β2a coexpressed with Ca~V~2.2, Bdel1, or Bdel2. This method utilizes CFP split into two nonfluorescent fragments: one fragment is fused to Ca~V~2.2\'s N terminus, and the other fragment is fused to Ca~V~β2a\'s C terminus (Fig. S1 A). Fluorescence occurs when the two halves of CFP reside close enough to each other to bind, forming an intact fluorescing CFP. We found that each channel produced a fluorescent signal at the plasma membrane (Fig. S1 B), indicating that the differences in modulation were not caused by a loss of cell surface Ca~V~β2a expression. These results differ from our previous study with β3 core ([@bib46]) because the CFP fragment was fused to a full-length β2a, which adds sufficient flexibility to allow BiFC regardless of orientation.

To determine whether the amino acid deletions affect tonic facilitation of control currents, we measured the prepulse facilitation ratio, which is measured by the P2/P1 current amplitude ratio ([Fig. 4, B--D](#fig4){ref-type="fig"}). Although Ca~V~2.2 currents showed small but significant prepulse facilitation ([Fig. 4 D](#fig4){ref-type="fig"}), both Bdel1 and Bdel2 currents decreased in amplitude after a prepulse. Interestingly, Bdel1 exhibited a significantly greater decrease in current amplitude after a prepulse than did Bdel2, resulting in a significantly (P \< 0.05) lower P2/P1 current ratio for Bdel1 than Bdel2 ([Fig. 4 D](#fig4){ref-type="fig"}).

Inhibition of Bdel2/β2a currents by SP mimics inhibition of wt Ca~v~2.2/β3 currents
-----------------------------------------------------------------------------------

By deleting two amino acids in the IS6-AID segment, N-current modulation changes from enhancement to robust inhibition. If the palmitoyl groups of Ca~V~β2a were critical for toggling modulation but are now displaced to reveal AA\'s inhibitory site on Bdel2, Bdel2/β2a inhibition should exhibit properties similar to Bdel2/β3 or Ca~V~2.2/β3. Because Bdel2/β3 currents inactivate so rapidly, their peak current could not be compared with modulation of Bdel2/β2a currents ([@bib46]). Therefore, we took a pharmacological approach to determine whether the same slow pathway that inhibits Ca~V~2.2/β3 currents confers Bdel2/β2a current inhibition. First, we tested whether inhibition of Ca~V~2.2/β3 and Bdel2/β2a currents by SP occurs via a BAPTA-sensitive pathway ([@bib2]; [@bib3]; [@bib30]). When the normally low (0.1 mM) BAPTA concentration was raised to 20 mM BAPTA, N-current inhibition by SP was no longer significant for Ca~V~2.2/β3 channels and was decreased with Bdel2/β2a channels ([Fig. 5, compare A with B](#fig5){ref-type="fig"}; and [Fig. 5 E](#fig5){ref-type="fig"}). Second, we tested whether BSA minimizes N-current inhibition by SP. Previously, we found that when BSA is included in the bath solution, inhibition of native and recombinant N current by M~1~R stimulation is lost ([@bib25]; [@bib28]; [@bib15]). Because BSA sequesters free AA released from phospholipids ([Fig. 5 C](#fig5){ref-type="fig"}) after receptor activation ([@bib28]), decreased N-current inhibition is attributed to decreased availability of free AA. When we tested both Ca~V~2.2/β3 and Bdel2/β2a channels ([Fig. 5, D and E](#fig5){ref-type="fig"}) in the presence of BSA, N-current inhibition by SP was no longer observed.

![Bdel2 current inhibition by SP is voltage independent, BAPTA sensitive, and antagonized by BSA similar to slow pathway modulation of Ca~V~2.2. HEK-M1 cells were transiently transfected with NK-1R, either Bdel2 or wt Ca~V~2.2, α~2~δ-1, and either Ca~V~β2a or Ca~V~β3. (A and B) Individual traces from wt Ca~V~2.2/β3 (left) and Bdel2/β2a currents (right) taken before and 90 s after application of SP with 0.1 mM BAPTA (A) or 20 mM BAPTA (B) in the pipette solution. (C) Schematic showing BSA\'s site of action. (D) 1 mg/ml BSA in the external bath medium. Left, wt Ca~V~2.2/β3; right, Bdel2/β2a. (E) Summary of the percent current remaining after SP from Ca~V~2.2/β3 and Bdel2/β2a channels; \*, P \< 0.05 compared with control currents (*n* = 6--9); †, P \< 0.05 using a one-way paired *t* test compared with unstimulated current amplitudes. Error bars represent SEM. Bars, 10 ms and 200 pA.](JGP_200910204_RGB_Fig5){#fig5}

Additionally, Ca~V~2.2/β3 current inhibition by SP was not relieved by a prepulse ([Fig. 4, D and E](#fig4){ref-type="fig"}), consistent with inhibition occurring via a voltage-independent pathway ([@bib19]). Comparison of Bdel2/β2a and Ca~V~2.2/β3 current inhibition ([Fig. 4, B--E](#fig4){ref-type="fig"} and [Fig. 5 E](#fig5){ref-type="fig"}) shows that for both currents, inhibition involves a voltage-independent, BAPTA-sensitive pathway that appears to use a free fatty acid, most likely AA, as a signaling molecule within the pathway. These findings are consistent with Bdel2/β2a current inhibition by SP occurring by a similar mechanism as Ca~V~2.2/β3 current inhibition by the slow pathway ([Fig. 1 A](#fig1){ref-type="fig"}; [@bib15]).

Free palmitic acid blocks inhibition of Bdel2 currents
------------------------------------------------------

In our companion study, exogenously applied palmitic acid blocked inhibition of Ca~V~2.2/β3 currents by SP ([@bib15]). If N-current inhibition of Bdel2/β2a and Ca~V~2.2/β3 channels involves a similar pathway, exogenously applied palmitic acid also should minimize inhibition of Bdel2/β2a currents after SP application ([Fig. 6 A](#fig6){ref-type="fig"}). To test this hypothesis, cells expressing Bdel2 and Ca~V~β2a were preincubated with 10 µM palmitic acid for at least 8 min before application of SP. In the continued presence of palmitic acid, SP inhibited N current by 21 ± 4% ([Fig. 6, C and D](#fig6){ref-type="fig"}). This inhibition was significantly reduced (P \< 0.05) by \>50% compared with inhibition in the absence of palmitic acid (46 ± 7%; [Fig. 6 D](#fig6){ref-type="fig"}). These findings are consistent with a model in which the palmitoyl groups of Ca~V~β2a ([Fig. 6 A](#fig6){ref-type="fig"}) antagonize N-current inhibition by free AA that is released after SP application.

![Exogenously applied palmitic acid blocks Bdel2 current inhibition by SP. HEK-M1 cells were transiently transfected with Bdel2, α~2~δ-1, Ca~V~β2a, and NK-1R. (A) Schematic representing preincubation of cells with 10 µM palmitic acid blocks free AA, released after stimulation of NK-1R, from occupying the inhibitory site. Enhancement site, not depicted. The two exogenous palmitic acids (magenta) are shown bound to the inner region of Bdel2, antagonizing AA from binding to the inhibitory sites. (B and C) Individual traces taken before and 2 min after application of 5 nM SP alone (B) or in the presence of 10 µM palmitic acid (C). (D) Summary of Bdel2 inhibition by SP in the presence of 10 µM palmitic acid (PA). \*, P \< 0.05 compared with current amplitude before SP (*n* = 7) or compared with the presence of palmitic acid alone (*n* = 6). \*\*, P \< 0.05; percent inhibition by SP compared with percent inhibition by palmitic acid + SP. Error bars represent SEM. Bars, 10 ms and 200 pA.](JGP_200910204R_RGB_Fig6){#fig6}

DISCUSSION
==========

In our previous study, we found that coexpression of Ca~V~β2a with Ca~V~2.2 and α~2~δ-1 results in enhancement of recombinant N current by M~1~R or NK-1R stimulation, whereas coexpression with Ca~V~β1b, Ca~V~β3, or Ca~V~β4 results in inhibition ([@bib15]). In the presence of Ca~V~β2a, M~1~R activation enhances native and recombinant N but not L current ([@bib25]; [@bib28]; [@bib15]; [@bib37]). Additionally, enhancement of recombinant Ca~V~2.2 and Ca~V~2.3 currents by NK-1Rs has been described previously ([@bib32]; [@bib15]). Because these three channels show similar transmembrane organization ([@bib6]), the differences in modulation are unlikely to arise from nonspecific membrane effects that might alter gating. Additional studies using free palmitic acid, depalmitoylated Ca~V~β2a, and chimeric Ca~V~βs indicated that Ca~V~β2a\'s palmitoyl groups may confer the switch by blocking AA\'s inhibitory actions to reveal latent enhancement ([@bib15]). In this study, we manipulated the N-channel\'s pore-forming subunit Ca~V~2.2 to alter Ca~V~β2a\'s orientation relative to Ca~V~2.2. We hypothesized that one (Bdel1) or two (Bdel2) deletions in the rigid IS6-AID segment would displace Ca~V~β2a sufficiently from its normal orientation such that its palmitoyl groups no longer interact with the inhibitory site. Moreover, we predicted that with Ca~V~β2a reoriented, the N-current enhancement, normally observed after SP application, would be masked by rescued inhibition.

We found that deleting a single amino acid in the IS6-AID segment to form Bdel1 ([@bib46]) resulted in highly variable N-current enhancement of Bdel1/β2a channels ([Fig. 3](#fig3){ref-type="fig"}). Deleting two amino acids in the IS6-AID segment to form Bdel2 resulted in robust N-current inhibition replacing enhancement by SP ([Fig. 4](#fig4){ref-type="fig"}). In turn, preincubation with 10 µM palmitic acid minimized inhibition of Bdel2/β2a currents ([Fig. 6](#fig6){ref-type="fig"}), as was observed with wt Ca~V~2.2/β3 currents ([@bib15]), suggesting that the palmitoyl groups of Ca~V~β2a no longer reside in their wt position. Current inhibition of both Ca~V~2.2/β3 and Bdel2/β2a channels ([Figs. 4--5](#fig4){ref-type="fig"}[](#fig5){ref-type="fig"}) exhibited similar properties to native N-current inhibition by the slow pathway in sympathetic neurons ([@bib25]), suggesting that displacement of Ca~V~β2a rescued inhibition mediated by phospholipid breakdown. These findings support a model in which Ca~V~β2a\'s palmitoyl groups may compete with and antagonize AA binding to a site on Ca~V~2.2 that confers N-current inhibition by the slow pathway.

Ca~V~2.2/β2a current enhancement and Bdel2/β2a current inhibition both occur by a voltage-independent, BAPTA-sensitive pathway
------------------------------------------------------------------------------------------------------------------------------

Several of our findings advance the notion that the G~q~PCRs NK-1R and M~1~R use the same slow pathway to mediate both enhancement and inhibition ([Fig. 1 A](#fig1){ref-type="fig"}). First, both enhancement and inhibition of Ca~V~2.2 currents by SP require low concentrations of BAPTA (0.1 mM) to observe modulation; the presence of 20 mM BAPTA in the pipette solution minimized modulation ([Figs. 2](#fig2){ref-type="fig"} and [5](#fig5){ref-type="fig"}). Native N-current inhibition by M~1~Rs in SCG neurons ([@bib2]; [@bib3]; [@bib30]; [@bib38]; [@bib26]) and hippocampal pyramidal neurons ([@bib42]) and Ca~V~2.3 current inhibition by NK-1Rs ([@bib32]) are also BAPTA sensitive. Second, unlike membrane-delimited inhibition ([@bib10]), a prepulse preceding the test pulse has no effect on the magnitude of N-current enhancement ([Fig. 2 B](#fig2){ref-type="fig"}) or inhibition ([Fig. 4 E](#fig4){ref-type="fig"}) by SP. Both NK-1Rs and M~1~Rs inhibit native N current via a voltage-independent pathway in SCG neurons ([@bib2]; [@bib30]; [@bib38]; [@bib19]; [@bib26]). Third, enhancement and inhibition exhibit similar pharmacological profiles. Preincubation of SCG neurons with the AA scavenger BSA or with the PLA~2~ antagonist oleoyloxyethyl phosphorylcholine minimized enhancement and inhibition of native N current by M~1~R agonists ([@bib25]). Ca~V~2.2 current modulation by NK-1Rs exhibits these same two properties, whereas BSA ([Fig. 5, D and E](#fig5){ref-type="fig"}) and oleoyloxyethyl phosphorylcholine (not depicted) minimize both enhancement and inhibition. These findings suggest that although enhancement and inhibition may occur at distinct sites on N channels, they may be different manifestations of the same or overlapping signaling pathways. Thus, whether SP inhibits or enhances N current is determined by which Ca~V~β is coexpressed with Ca~V~2.2 rather than from differences in signaling.

Further support for this idea comes from our finding that Bdel2/β2a channels exhibited N-current inhibition by SP similar to Ca~V~2.2/β3 channels. Therefore, we attempted to determine whether this inhibition also was caused by the slow pathway. Coexpression of Ca~V~β2a, compared with other Ca~V~βs, results in increased prepulse-induced relief of tonic N-current inhibition and will undergo increased voltage-dependent, membrane-delimited inhibition by pertussis toxin--sensitive G proteins after stimulation of certain GPCRs ([@bib4]; [@bib11]). Released Gβγ is thought to bind to the Ca~V~2.2\'s I--II linker, disrupting the association between the channel and Ca~V~β ([@bib18]; [@bib10]). However, the inhibited Bdel2/β2a currents did not show voltage-dependent relief from inhibition after a prepulse in low BAPTA conditions ([Fig. 4](#fig4){ref-type="fig"}). Additionally, inhibition was decreased or lost when cells were either dialyzed with 20 mM BAPTA or when BSA was included in the bath solution, respectively. These characteristics of inhibition match slow pathway inhibition of N current observed in SCG neurons ([@bib30]; [@bib38]; [@bib25]). The overlapping biophysical and pharmacological profile of modulation indicates that the same signaling pathway mediates N-current enhancement of Ca~V~2.2/β2a channels and inhibition of Ca~V~2.2/β3 and Bdel2/β2a channels. Moreover, the observed enhancement of Ca~V~2.2/β2a versus inhibition of Bdel2/β2a channels suggests that changes in orientation of Ca~V~β2a underlie the switch in modulation. However, it was possible that Ca~V~β2a did not stay bound to Bdel2 and therefore was no longer present to block inhibition.

Bdel1 and Bdel2 alter Ca~V~β2a\'s position relative to the α1 subunit
---------------------------------------------------------------------

Therefore, critical to understanding how the mutations in the IS6-AID segment disrupt enhancement was determining whether Ca~V~β2a remained associated with mutated N channels because β subunits appear able to dissociate from channels in the plasma membrane ([@bib17]; [@bib16]). Several pieces of data indicate that although Bdel1 and Bdel2 have a disrupted IS6-AID segment, Ca~V~β subunits continue to bind to Ca~V~2.2. When β subunits are left out of the transfection protocol, \<10% of the normal amount of current is detected with Ca~V~2.2 ([@bib5]; [@bib23]), Bdel1 ([@bib46]), or Bdel2 (this study) even when T antigen is included. These observations, along with studies of other calcium channels ([@bib39]; [@bib48]), support the notion that to observe a robust current, a β subunit must be associated with the channel in mammalian cells. Our BiFC imaging data (Fig. S1) document that Ca~V~β2a binds to Bdel1 and Bdel2 at the plasma membrane. Because association of the two complementary parts of cerulean stabilizes the complex, the data cannot tell us whether Ca~V~β2a dissociates. However, in previous studies in which dissociation of β subunits was documented, reassociation was also detected ([@bib17]; [@bib16]), suggesting that if Ca~V~β2a can bind to Ca~V~2.2, it will bind. Additional BiFC measurements of Bdel1 and Bdel2 coexpressed with a Ca~V~β core protein containing a truncated C terminus indicate that the β subunit is displaced relative to the pore in positions distinct from wt and from one another ([@bib46]).

Displacement of Ca~V~β2a from its normal orientation to Ca~V~2.2 converts N-current enhancement to inhibition
-------------------------------------------------------------------------------------------------------------

The putative displacement of the palmitoyl groups may disrupt N-channel modulation by the slow pathway. With a single amino acid deletion in Bdel1, N current no longer exhibited significant enhancement by SP as a result of the increased variability of modulation. In contrast, when Bdel1 was coexpressed with Ca~V~β3, SP significantly inhibited current, indicating that the inhibitory site on the α1 subunit remains functional. This latter finding rules out the possibility that disrupted gating underlies the increased variability in enhancement because Bdel1/Ca~V~β3 channels also exhibit disrupted gating ([@bib46]) yet are inhibited by SP. Moreover, this finding indicates that the low-affinity interactions between Ca~V~β3 and Bdel1 play at most a minor role in slow pathway inhibition of N current ([@bib14]). Although the increased variability of Bdel1 current enhancement appears independent of altered protein--protein interactions, it is possible that the switch from current enhancement to inhibition for Bdel2 occurs as a result of changes in low-affinity interactions between Ca~V~β2a and Bdel2 arising from deletions in the I--II linker. However, we ruled out this possibility because exogenously applied palmitic acid significantly reduced current inhibition despite the novel orientation of Ca~V~β2a to Bdel2 ([Fig. 6](#fig6){ref-type="fig"}). Using a similar experimental design, we previously showed that exogenous application of palmitic acid blocked SP-mediated inhibition of Ca~V~2.2/β3 currents ([@bib15]). It is also unlikely that toggling from enhancement to inhibition occurs as a result of altered membrane curvature because the bulk concentration of phospholipids and fatty acids near the channel would not be expected to change despite the reorientation of Ca~V~β2a\'s palmitoyl groups. Moreover, the BiFC images show that Ca~V~β2a is situated close to Bdel2 so that the endogenous palmitoyl groups should still reside extremely close to the channel. Thus, the switch from enhancement to inhibition after SP is most simply explained by a model in which the observed inhibition results from a loss of interaction by the displaced palmitoyl groups with the inhibitory site of Bdel2/Ca~V~β2a channels. The free palmitic acid then competes with endogenously released AA for the inhibitory site on the channel.

Although inhibition decreased with free palmitic acid, enhancement was not rescued. It is possible that the preincubation conditions were suboptimal for complete reversibility. However, palmitic acid will cross lipid bilayers within seconds with a permeability coefficient 400 times higher than that for water and diffusion rates 100 times faster than AA ([@bib13]; [@bib20]). These biophysical properties of palmitic acid would suggest that its uptake into the membrane is not a limiting factor. Lastly, the choice of 10 µM palmitic acid seems appropriate because this concentration is within the measured physiological range ([@bib47]). Notably, in pathophysiological conditions such as diabetic ketoacidosis, levels may rise up to 100 times this concentration ([@bib40]). Thus, the lack of recovery of enhancement appears independent of the properties of exogenous free palmitic acid.

To minimize inhibition, we found that the Ca~V~β2a protein docks the palmitic acids while at the same time the palmitoyl groups hold the β subunit in a very specific orientation to Ca~V~2.2. Our data would indicate that there is nothing casual about this interaction. Enhancement may also require specific protein--protein interactions because each Ca~V~β appears to establish a unique set of low-affinity interactions with Ca~V~2.2 as well as bind to the AID ([@bib35]; [@bib49]; [@bib50]; [@bib22]). Because all N channels appear capable of exhibiting enhancement, Ca~V~β\'s proper orientation to Ca~V~2.2 through binding to the AID may somehow expose or stabilize the enhancement site. Because this orientation is disrupted with Bdel2, enhancement is also disrupted. Future studies with altered I--II linker sequence may resolve this question.

Physiological significance of N-channel regulation by palmitoylation
--------------------------------------------------------------------

Mutations in the IS6-AID segment appear to disrupt critical protein--lipid interactions between the palmitoyl moieties of Ca~V~β2a and Ca~V~2.2 that in turn uncouple the otherwise tight regulation of Ca~V~2.2 by G~q~PCRs. Entry of Ca^2+^ ions through N channels regulates the opening of small-conductance K^+^~Ca~ channels during the posthyperpolarization ([@bib41]; [@bib29]). N channels expressed postsynaptically on the dorsal horn affect neuronal excitability during and after transmission of nociceptive stimuli. Whether up- or down-regulation of the different Cavβs can occur in response to a nociceptive stimulus remains untested; however, both increases and decreases in Ca^2+^ currents have been observed in different neuronal subtypes after nerve injury (for review see [@bib84]). Thus, any disruption in modulation of N current by SP (for example, during transmission of nociceptive stimulation) may alter the frequency of action potential firing in the spinal cord that conveys nociceptive information to the brain for further processing.

In summary, the data presented here, together with the findings of [@bib15], uncover a new function for protein palmitoylation. In addition to conferring unique gating properties, Ca~V~β2a\'s palmitoyl groups appear responsible for blocking inhibition to reveal enhancement by the slow pathway. In order for all of these processes to proceed normally, the palmitoylated Ca~V~β2a must be in a specific orientation. The precise docking of the palmitoyl groups allows Ca~V~β2a to effectively reach up into the membrane with its fatty acid "fingers" to alter Ca~V~2.2\'s gating properties and modulation. This new idea of a lipid modification of a cytosolic protein (Ca~V~β2a) interacting with a transmembrane protein (Ca~V~2.2) to change its regulation extends the role of palmitoylation beyond its known functions of targeting or tethering proteins to the membrane ([@bib36]). Recently, [@bib52] made the novel observation that palmitoylation of a membrane-associated form of retinal epithelial protein 65 (RPE65) not only enhanced its targeting to membranes but most importantly enhanced its selectivity for binding to all-trans-retinyl-esters. However, these findings could be explained by a simple tethering mechanism for palmitoylation. Lastly, our findings predict that palmitoylation may confer to other cytoplasmic proteins the potential to interact with particular transmembrane proteins to alter their function.
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